TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions

Pradeep B J Reddy, Taylor H. Schreiber, Naveen K. Rajasagi, Amol Suryawanshi, Sachin Mulik, Tamara Veiga-Parga, Toshiro Niki, Mitsuomi Hirashima, Eckhard R. Podack, Barry T. Rouse

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Ocular infection with herpes simplex virus 1 (HSV-1) results in a chronic immunoinflamammtory reaction in the cornea, which is primarily orchestrated by CD4+ T cells. Hence, targeting proinflammatory CD4+ T cells or increasing the representation of cells that regulate their function is a relevant therapeutic strategy. In this report, we demonstrate that effective therapeutic control can be achieved using a combination of approaches under circumstances where monotherapy is ineffective. We use a convenient and highly effective monoclonal antibody (MAb) approach with MAbT25 to expand cells that express the tumor necrosis factor receptor superfamily member 25 (TNFRSF25). In naïve animals, these are predominantly cells that are Foxp3-positive regulatory T cells. MAbT25 treatment before or at the time of initial HSV infection was an effective means of reducing the severity of subsequent stromal keratitis lesions. However, MAbT25 treatment was not effective if given 6 days after infection since it expanded proinflammatory effector T cells, which also express TNFRSF25. Therefore, the MAbT25 procedure was combined with galectin-9 (Gal-9), an approach that compromises the activity of T cells involved in tissue damage. The combination therapy provided highly effective lesion control over that achieved by treatment with one of them. The beneficial outcome of the combination therapy was attributed to the expansion of the regulatory T cell population that additionally expressed activation markers such as CD103 needed to access inflammatory sites. Additionally, there was a marked reduction of CD4+ gamma interferonproducing effector T cells responsible for orchestrating the tissue damage. The approach that we describe has potential application to control a wide range of inflammatory diseases, in addition to stromal keratitis, an important cause of human blindness.

Original languageEnglish
Pages (from-to)10606-10620
Number of pages15
JournalJournal of Virology
Volume86
Issue number19
DOIs
StatePublished - Oct 1 2012
Externally publishedYes

Fingerprint

Receptors, Tumor Necrosis Factor, Member 25
Galectins
herpes simplex
tumor necrosis factors
Simplexvirus
lesions (animal)
T-lymphocytes
T-Lymphocytes
viruses
therapeutics
receptors
antibodies
Antibodies
Keratitis
Regulatory T-Lymphocytes
keratitis
Therapeutics
Eye Infections
Human Herpesvirus 1
Blindness

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Reddy, P. B. J., Schreiber, T. H., Rajasagi, N. K., Suryawanshi, A., Mulik, S., Veiga-Parga, T., ... Rouse, B. T. (2012). TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions. Journal of Virology, 86(19), 10606-10620. https://doi.org/10.1128/JVI.01391-12

TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions. / Reddy, Pradeep B J; Schreiber, Taylor H.; Rajasagi, Naveen K.; Suryawanshi, Amol; Mulik, Sachin; Veiga-Parga, Tamara; Niki, Toshiro; Hirashima, Mitsuomi; Podack, Eckhard R.; Rouse, Barry T.

In: Journal of Virology, Vol. 86, No. 19, 01.10.2012, p. 10606-10620.

Research output: Contribution to journalArticle

Reddy, PBJ, Schreiber, TH, Rajasagi, NK, Suryawanshi, A, Mulik, S, Veiga-Parga, T, Niki, T, Hirashima, M, Podack, ER & Rouse, BT 2012, 'TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions', Journal of Virology, vol. 86, no. 19, pp. 10606-10620. https://doi.org/10.1128/JVI.01391-12
Reddy, Pradeep B J ; Schreiber, Taylor H. ; Rajasagi, Naveen K. ; Suryawanshi, Amol ; Mulik, Sachin ; Veiga-Parga, Tamara ; Niki, Toshiro ; Hirashima, Mitsuomi ; Podack, Eckhard R. ; Rouse, Barry T. / TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions. In: Journal of Virology. 2012 ; Vol. 86, No. 19. pp. 10606-10620.
@article{7e908448a7034b3c9fcdd189d5c143c2,
title = "TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions",
abstract = "Ocular infection with herpes simplex virus 1 (HSV-1) results in a chronic immunoinflamammtory reaction in the cornea, which is primarily orchestrated by CD4+ T cells. Hence, targeting proinflammatory CD4+ T cells or increasing the representation of cells that regulate their function is a relevant therapeutic strategy. In this report, we demonstrate that effective therapeutic control can be achieved using a combination of approaches under circumstances where monotherapy is ineffective. We use a convenient and highly effective monoclonal antibody (MAb) approach with MAbT25 to expand cells that express the tumor necrosis factor receptor superfamily member 25 (TNFRSF25). In na{\"i}ve animals, these are predominantly cells that are Foxp3-positive regulatory T cells. MAbT25 treatment before or at the time of initial HSV infection was an effective means of reducing the severity of subsequent stromal keratitis lesions. However, MAbT25 treatment was not effective if given 6 days after infection since it expanded proinflammatory effector T cells, which also express TNFRSF25. Therefore, the MAbT25 procedure was combined with galectin-9 (Gal-9), an approach that compromises the activity of T cells involved in tissue damage. The combination therapy provided highly effective lesion control over that achieved by treatment with one of them. The beneficial outcome of the combination therapy was attributed to the expansion of the regulatory T cell population that additionally expressed activation markers such as CD103 needed to access inflammatory sites. Additionally, there was a marked reduction of CD4+ gamma interferonproducing effector T cells responsible for orchestrating the tissue damage. The approach that we describe has potential application to control a wide range of inflammatory diseases, in addition to stromal keratitis, an important cause of human blindness.",
author = "Reddy, {Pradeep B J} and Schreiber, {Taylor H.} and Rajasagi, {Naveen K.} and Amol Suryawanshi and Sachin Mulik and Tamara Veiga-Parga and Toshiro Niki and Mitsuomi Hirashima and Podack, {Eckhard R.} and Rouse, {Barry T.}",
year = "2012",
month = "10",
day = "1",
doi = "10.1128/JVI.01391-12",
language = "English",
volume = "86",
pages = "10606--10620",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "19",

}

TY - JOUR

T1 - TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions

AU - Reddy, Pradeep B J

AU - Schreiber, Taylor H.

AU - Rajasagi, Naveen K.

AU - Suryawanshi, Amol

AU - Mulik, Sachin

AU - Veiga-Parga, Tamara

AU - Niki, Toshiro

AU - Hirashima, Mitsuomi

AU - Podack, Eckhard R.

AU - Rouse, Barry T.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Ocular infection with herpes simplex virus 1 (HSV-1) results in a chronic immunoinflamammtory reaction in the cornea, which is primarily orchestrated by CD4+ T cells. Hence, targeting proinflammatory CD4+ T cells or increasing the representation of cells that regulate their function is a relevant therapeutic strategy. In this report, we demonstrate that effective therapeutic control can be achieved using a combination of approaches under circumstances where monotherapy is ineffective. We use a convenient and highly effective monoclonal antibody (MAb) approach with MAbT25 to expand cells that express the tumor necrosis factor receptor superfamily member 25 (TNFRSF25). In naïve animals, these are predominantly cells that are Foxp3-positive regulatory T cells. MAbT25 treatment before or at the time of initial HSV infection was an effective means of reducing the severity of subsequent stromal keratitis lesions. However, MAbT25 treatment was not effective if given 6 days after infection since it expanded proinflammatory effector T cells, which also express TNFRSF25. Therefore, the MAbT25 procedure was combined with galectin-9 (Gal-9), an approach that compromises the activity of T cells involved in tissue damage. The combination therapy provided highly effective lesion control over that achieved by treatment with one of them. The beneficial outcome of the combination therapy was attributed to the expansion of the regulatory T cell population that additionally expressed activation markers such as CD103 needed to access inflammatory sites. Additionally, there was a marked reduction of CD4+ gamma interferonproducing effector T cells responsible for orchestrating the tissue damage. The approach that we describe has potential application to control a wide range of inflammatory diseases, in addition to stromal keratitis, an important cause of human blindness.

AB - Ocular infection with herpes simplex virus 1 (HSV-1) results in a chronic immunoinflamammtory reaction in the cornea, which is primarily orchestrated by CD4+ T cells. Hence, targeting proinflammatory CD4+ T cells or increasing the representation of cells that regulate their function is a relevant therapeutic strategy. In this report, we demonstrate that effective therapeutic control can be achieved using a combination of approaches under circumstances where monotherapy is ineffective. We use a convenient and highly effective monoclonal antibody (MAb) approach with MAbT25 to expand cells that express the tumor necrosis factor receptor superfamily member 25 (TNFRSF25). In naïve animals, these are predominantly cells that are Foxp3-positive regulatory T cells. MAbT25 treatment before or at the time of initial HSV infection was an effective means of reducing the severity of subsequent stromal keratitis lesions. However, MAbT25 treatment was not effective if given 6 days after infection since it expanded proinflammatory effector T cells, which also express TNFRSF25. Therefore, the MAbT25 procedure was combined with galectin-9 (Gal-9), an approach that compromises the activity of T cells involved in tissue damage. The combination therapy provided highly effective lesion control over that achieved by treatment with one of them. The beneficial outcome of the combination therapy was attributed to the expansion of the regulatory T cell population that additionally expressed activation markers such as CD103 needed to access inflammatory sites. Additionally, there was a marked reduction of CD4+ gamma interferonproducing effector T cells responsible for orchestrating the tissue damage. The approach that we describe has potential application to control a wide range of inflammatory diseases, in addition to stromal keratitis, an important cause of human blindness.

UR - http://www.scopus.com/inward/record.url?scp=84869040736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869040736&partnerID=8YFLogxK

U2 - 10.1128/JVI.01391-12

DO - 10.1128/JVI.01391-12

M3 - Article

C2 - 22811539

AN - SCOPUS:84869040736

VL - 86

SP - 10606

EP - 10620

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 19

ER -